Given the cumulative evidence supporting Stat3 as a potential therapeutic target in cancer and that there are ongoing clinical trials testing Stat3 inhibitors [49], our group has attempted to better understand the molecular mechanisms of Stat3 activity and the role of HGF/c-met in transducing its signal. Here, MET is linked to cancer.